INSERM, UMR 1064, Nantes, France; CHU Nantes, ITUN, Nantes, France; Faculté de Médecine, Université de Nantes, Nantes, France.
Eur J Immunol. 2013 Nov;43(11):2832-44. doi: 10.1002/eji.201343600. Epub 2013 Aug 21.
Heme oxygenase-1 (HO-1) inhibits immune responses and inflammatory reactions via the catabolism of heme into carbon monoxide (CO), Fe(2+) , and biliverdin. We have previously shown that either induction of HO-1 or treatment with exogenous CO inhibits LPS-induced maturation of dendritic cells (DCs) and protects in vivo and in vitro antigen-specific inflammation. Here, we evaluated the capacity of HO-1 and CO to regulate antigen presentation on MHC class I and MHC class II molecules by LPS-treated DCs. We observed that HO-1 and CO treatment significantly inhibited the capacity of DCs to present soluble antigens to T cells. Inhibition was restricted to soluble OVA protein, as no inhibition was observed for antigenic OVA-derived peptides, bead-bound OVA protein, or OVA as an endogenous antigen. Inhibition of soluble antigen presentation was not due to reduced antigen uptake by DCs, as endocytosis remained functional after HO-1 induction and CO treatment. On the contrary, CO significantly reduced the efficiency of fusion between late endosomes and lysosomes and not by phagosomes and lysosomes. These data suggest that HO-1 and CO can inhibit the ability of LPS-treated DCs to present exogenous soluble antigens to naïve T cells by blocking antigen trafficking at the level of late endosome-lysosome fusion.
血红素加氧酶-1(HO-1)通过血红素分解为一氧化碳(CO)、Fe(2+)和胆红素来抑制免疫反应和炎症反应。我们之前已经表明,HO-1 的诱导或外源性 CO 的治疗均可抑制 LPS 诱导的树突状细胞(DC)成熟,并在体内和体外保护抗原特异性炎症。在这里,我们评估了 HO-1 和 CO 调节 LPS 处理的 DC 上 MHC Ⅰ类和 MHC Ⅱ类分子抗原呈递的能力。我们观察到 HO-1 和 CO 处理可显著抑制 DC 将可溶性抗原呈递给 T 细胞的能力。抑制作用仅限于可溶性 OVA 蛋白,因为没有观察到抗原性 OVA 衍生肽、珠结合的 OVA 蛋白或作为内源性抗原的 OVA 的抑制作用。可溶性抗原呈递的抑制不是由于 DC 摄取抗原减少所致,因为 HO-1 诱导和 CO 处理后内吞作用仍然有效。相反,CO 显著降低晚期内体与溶酶体融合的效率,而不是吞噬体与溶酶体。这些数据表明,HO-1 和 CO 可以通过阻断晚期内体-溶酶体融合水平的抗原运输来抑制 LPS 处理的 DC 将外源性可溶性抗原呈递给幼稚 T 细胞的能力。